Clinical results with irinotecan (CPT-11 [Camptosar]) and other camptothecin derivatives in various cancers, although encouraging, have fallen short of the expectations predicted by preclinical models. One proposed
Peter J. Houghton, PhD
Advertisement
Articles by Peter J. Houghton, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Palbociclib Combo in HR+, HER2+ Metastatic Breast Cancer
2
Sacituzumab Govitecan Receives FDA Approval Across 2 TNBC Indications
3
NCCN Updates Bladder Cancer Guidelines for ctDNA MRD Testing
4
Sigvotatug Vedotin Does Not Significantly Improve Survival in NSCLC Trial
5